Alkem Lab

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE540L01014
  • NSEID: ALKEM
  • BSEID: 539523
INR
5,732.50
120.85 (2.15%)
BSENSE

Dec 05

BSE+NSE Vol: 26.92 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Alkem Laboratories Ltd stock-summary
stock-summary
Alkem Laboratories Ltd
Mid Cap
Pharmaceuticals & Biotechnology
Headquartered in Mumbai, India, Alkem Laboratories Limited is a leading Indian pharmaceutical company with global operations. The company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and international markets.
Company Coordinates stock-summary
Company Details
Alkem House SenapatiBapat Marg, Lower Parel Mumbai Maharashtra : 400013
stock-summary
Tel: 91-22-39829999
stock-summary
investors@alkem.com
Registrar Details
Link Intime India Pvt Ltd, C-13 Pannalal Silk Compound, L B S Marg, Bhandup , Mumbai
stock-summary Capital Structure
Capital Structure stock-summary
Present Equity Capital
INR 23.91 Cr
Number of Shares
11.96 Cr
Face Value
INR 2.0
Date
Number
of Shares(Cr)
Equity
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
23-Dec-2015
11.96
23.91
12853442
2
Public Issues
23-Dec-2015
11.96
23.91
12853442
2
Public Issues
22-Dec-2015
10.67
21.34
-12853442
2
Offer For Sale
22-Dec-2015
10.67
21.34
-12853442
2
Offer For Sale
16-Mar-2015
5.98
11.96
47826000
2
Stock Split
16-Mar-2015
11.96
23.91
59782500
2
Bonus
16-Mar-2015
5.98
11.96
47826000
2
Stock Split
16-Mar-2015
11.96
23.91
59782500
2
Bonus
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 32 Schemes (16.94%)

FIIs

Held by 520 FIIs (9.48%)

Promoter with highest holding

Sarandhar Singh * (please Refer Notes) (18.75%)

Highest Public shareholder

Icici Prudential Multi-asset Fund (5.5%)

Individual Investors Holdings

17.18%

stock-summary Board of Directorsstock-summary
stock-summary
Management
Designation
Remuneration
Basudeo N Singh
Executive Chairman
19.25 cr
SANDEEP SINGH
Managing Director
8.27 cr
Mritunjay Kumar Singh
Executive Director
9.59 cr
A K Purwar
Non-Exec. & Independent Dir.
31.0 lacs
SANGEETA KAPILJIT SINGH
Non-Exec. & Independent Dir.
32.0 lacs
SUDHA RAVI
Non-Exec. & Independent Dir.
29.0 lacs
Manish Narang
Company Sec. & Compli. Officer
0
Dheeraj Sharma
Non-Exec. & Independent Dir.
31.0 lacs
Narendra Aneja
Non-Exec. & Independent Dir.
30.0 lacs
SARVESH SINGH
Executive Director
4.33 cr
Madhurima Singh
Executive Director
9.5 cr
Sujjain Talwar
Independent Director
19.0 lacs
Srinivas Singh
Executive Director
5.72 cr
stock-recommendationRaw Materials
Raw Materials Dashboard stock-summary
Raw Materials
Amount(Rs Cr)
% of RM Cost
 
Icon
No Data Available
stock-recommendation Finished Goods
Finished Goods Dashboard stock-summary
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Other Operating Revenues
82.73
1.39%
 
1.39
Other Operating Revenues
98.61
Other Operating Revenues
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
4,001 Cr
(Quarterly Results - Sep 2025)
Net Profit:
765 Cr
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR 68,541 Cr (Mid Cap)

stock-summary
P/E

28.00

stock-summary
Industry P/E

34

stock-summary
Dividend Yield

0.82%

stock-summary
Debt Equity

-0.05

stock-summary
Return on Equity

17.61%

stock-summary
Price to Book

4.93